Novel sample preparation technology identified as an important innovation for company’s cancer screening tests, and for external clinicians and researchers. (Aug. 11, 2017) Click to view
Yearly Archive: 2017
Company takes critical step in the commercialization of its PWS Nanocytology cancer screening technology platform. (Aug. 3, 2017) Click to view
Preora Pres. & CEO John Hart expresses support and gratitude for PROPEL’s contributions to Chicago’s growing medtech startup community. (June 27, 2017) Click to view
Preora Diagnostics President & CEO John Hart participates in conference highlighting how impact investing can advance leading-edge technologies under development in Chicago. (March 22, 2017) Click to view
According to findings from American Cancer Society researchers, very few people who could benefit from lung cancer screening – mostly current and former smokers – are actually getting the tests. (Feb. 2, 2017) Click to view.